Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics.
about
Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients.A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids.Section 3. A discussion of flexible dosing and patient-centered therapy: highlights of the asthma summit 2009: beyond the guidelines.Beclomethasone/formoterol fixed combination for the management of asthma: patient considerations.Pharmacogenetics and the development of personalized approaches for combination therapy in asthma.Inhaled corticosteroids in chronic obstructive pulmonary disease: a review.Inhaled corticosteroids for asthma: on-demand or continuous use.Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment.The long-acting β2 -adrenoceptor agonist, indacaterol, enhances glucocorticoid receptor-mediated transcription in human airway epithelial cells in a gene- and agonist-dependent mannerAnti-proliferative and anti-remodelling effect of beclomethasone dipropionate, formoterol and salbutamol alone or in combination in primary human bronchial fibroblasts.Extrafine beclomethasone dipropionate/formoterol hydrofluoroalkane-propelled inhaler in asthma.β(2) -adrenoreceptor polymorphisms in asthmatic and non-asthmatic schoolchildren from Colombia and their relationship to treatment response.Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways.Use and safety of long-acting β2-agonists for pediatric asthmaInhaled beclometasone dipropionate/formoterol extra-fine fixed combination in the treatment of asthma: evidence and future perspectives
P2860
Q35070070-66231088-A74D-4C59-A798-59D720349428Q36510045-6582B7AE-5F55-4F1A-975E-13E06A21CE91Q36834747-E94DEDD4-07B0-4C50-8696-6DBB6F98BFECQ37390386-8FC566E2-6748-471E-AC15-780B5A998468Q37425660-2846D0EB-4F66-484F-8AB9-3C7E6C714502Q37681569-EC12315E-6F4C-4CC3-99F5-6D997E42287BQ38154624-CAD4A0D6-3DB1-4D64-9483-0BE537586B2AQ38550921-46BD1C6B-ABD2-4553-8343-3DB3378262B2Q39960078-F7BAD3FB-E3FA-4ADB-A50D-B1B84A60248FQ40036240-0420F75C-2040-46E6-968C-CB6719E70881Q40109458-01894DBC-442B-47C3-AB61-0B3E43226285Q54324492-BDB0BC11-5309-4C1E-BE67-68FEF32AA0A0Q55041230-C4754026-DCC2-4866-8609-3493B477CE1CQ57821604-025A41CC-B582-4C7B-8A3A-323645D529C3Q58877120-D13F4D46-E656-4B73-A9F4-0D0B3F8FAEE6
P2860
Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Biochemical interaction betwee ...... m mild to moderate asthmatics.
@en
Biochemical interaction betwee ...... m mild to moderate asthmatics.
@nl
type
label
Biochemical interaction betwee ...... m mild to moderate asthmatics.
@en
Biochemical interaction betwee ...... m mild to moderate asthmatics.
@nl
prefLabel
Biochemical interaction betwee ...... m mild to moderate asthmatics.
@en
Biochemical interaction betwee ...... m mild to moderate asthmatics.
@nl
P2093
P921
P1433
P1476
Biochemical interaction betwee ...... m mild to moderate asthmatics.
@en
P2093
A M Vignola
G Nicolini
J Bousquet
M Gjomarkaj
R Di Giorgi
R Gagliardo
P2860
P304
P356
10.1111/J.1398-9995.2005.00702.X
P577
2005-03-01T00:00:00Z